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I any millions of the people living in tropical regions of the world are cut off from the main stream of social and eco-.. nomic progress. Victims of a heavy burden of disease as 
well as of harsh economic circumstances, they are not free to 
choose and plan a better future. 
There is a growing awareness of these special problems of the 
tropical countries, and one main channel of response is through 
the work of the World Health Organization (WHO) and the 
United Nations Development Programme (UNDP). It is clear 
that health is an integral part of development; healthy people are 
more effective and, in turn, development is essential to provide 
the resources necessary for improved health. Health and develop-
ment are therefore inextricably interlinked and any strategy for 
improvement must be based upon this· reality. 
There is a wide range of existing knowledge and technology to 
be coordinated and exploited. A new dam to improve water 
supplies and provide irrigation and power, training in practical 
ways to avoid disease, better use of available drugs and vaccines, 
and a more favourable social and economic climate-these are 
some of the developments which will bring change and benefit. 
But in considering all the efforts now being made, it is clear that 
there is one aspect which, although of high priority, is not receiving 
adequat~ attention. The technical tools now available to control 
many of the tropical diseases are inadequate, or ineffective. It has, 
for example, repeatedly been shown that existing insecticides and 
IDRC-U~ 
drugs for malaria cont~ol are unable to stop transmission of th~fj '/ 
disease throughout very large areas of Africa. Present remedies 
for other major tropical diseases-schistosomiasis, filariasis, 
trypanosomiasis, leprosy and leishmaniasis-are not practicable 
for large-scale use in many tropical countries. New tools are 
therefore needed. 
WHO and UNDP recently launched a new Special Programme 
for Research and Training in Tropical Diseases to obtain these 
new tools. Fundamental to this Programme is the involvement 
; --- of the world's leading scientists and research institutions. But of 
equal importance is the fullest possible involvement of the tropical 
countries themselves so that they may become competent, through 
training and research, to deal with their own disease problems. 
We commend this booklet to your reading as an account of the 
challenges and opportunities. We hope to enlist your support for 
a plan of action which holds a genuine promise for human better-
ment. 





A medical worker takes a blood sample from 
a child i11 Sudan, where mosquito resistance to DDT 
resulted 111 a recrudescence of malaria and 
threatened to ruin one of the most promising 
development programmes in Africa. 
THE BURDEN 
I 
everal huodred million people are affected by tropical diseases, and many 
more are at risk. Most of these diseases are chronic and long-drawn-out 
infections. Sometimes they lead to early death, but this onJy partly reflects 
the human suffering they cause. 
Tropical diseases affect every aspect of human life from childhood onwards, 
and even wbeo they don't kill they a re debilitating; they can disable an enti re 
population, prevent the planting or the reaping of crops, cause the abandonment 
of fertile and poten tially productive land, and increase the effort required for 
survival. 
At a time when most countries of the world plan and undertake activities to bring 
about social and economic improvements, tropical diseases stand as a major obsta-
cle because people who cannot achieve minimal good health cannot promote or 
fully benefit from development. 
The Gezi ra case history 
Many examples can be found of the impact of tropical diseases in destroying the 
hopes for a better life by undermining the efforts to achieve it. That of the Gezira 
project in Sudan is typical. 
Early this century. the possibilities for economjc development and social progress 
were remarkably well demonstrated in this triangle-shaped area lying between 
the White Nile and the Blue Nile south of Khartoum. The Gezira was a 
sparsely popuJated, semi-arid savanna when the completion of the Sennar Dam 
on the Blue Nile made possible the reclamation of nearly half a million hec-
tares of land. 
Spectacular transformations graduaJJy took place as living conditioos of farmers 
improved a nd new immigrants Wt're attracted by the magnet of a self-sufficient, 
decent life. Within a few decades, the Gezira became the most densely populated 
and the most prosperous agricultural region of Sudan. 
lt acquired a unique character. The typical Sudanese thatched rouod huts became 
interspersed with the rectanguJar whitewashed mud or brick houses built by the 
immigrants from Chad and Nigeria or provided by the government, and with the 
camel-hair tents of the nomads who came during the cotton-picking season. 
Schools, dispensaries, health centres, and hospitals jostled with white minarets and 
the traditional mar kets-social centres for a busy, white-clad. white-turbaned or 
white-veiled popuJation. 
Al first, reclaimed land was almost exclusively planted with cotton, the country's 
cash crop, known the world over for its superior quality. T his crop permitted a 
simple and effective mosqujto contro l measure: periphera l irrigation ditches were 
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4 left to dry out every few days, never remaining full for a whole week-the time 
required for the complete development of mosquitos from egg to adult. This, 
together with the use of larvicides and the speedy treatment of the relatively few 
malaria oases, kept the disease under control. 
Gradually, secondary crops were added : millet. wheat , groundnuts and, later on, 
rice. This meant that the periodical drying out of the canals had to be abandoned, 
with the result that larvae of Anopheles gambiae, the principal malaria-transmitting 
mosquito in the region, could reach maturity. 
Malaria strikes 
In 1950, after a season of particularly heavy rains, malaria struck. It spread rapidly 
from village to village, affecting thousands of people within weeks. More than half 
of the total labour force of the Gezira was infected by Plasmodium falciparum, the 
predominant parasite species in the region and responsible for the severest form 
of malaria. Hundreds of people died, and so many were weakened that fully one-
third of tbe crops went unharvested. To the incalculable human cost was added 
the economic loss of about 10 million dollars. 
This marked the beginning of a long, costly fight against malaria and its vectors-
mosquitos. These insects gradually developed resistance against major insecticides: 
first to dieldrin, then to DDT. A World Health Organizatioo survey in 1970 re-
vealed "an extraordinary bigb tolerance of mosquitos to DDT". The use of DDT 
was abaod ooed in the G ezira. Larviciding became irregular and by 1974 it was 
en tirely discontinued owing to a shortage of Jarviciding oil. Meanwhile. malaria 
progressed. 
In 1961, a survey of 16 villages bad shown that malaria was endemic in 7 of them. 
By 1975, it was endemic in all of tbe 16. In some villages, more than half of the 
people were infected with malaria. 
A major effort is now under way and an attempt is being made to use massively 
all available weapons against malaria. Armies of " mosquito men" have been 
trained to spray malathion, a new insecticide to which mosquitos are still 
susceptible. Households are regularly surveyed and drugs a re used on a large 
scale in the hope of reducing transmission. Larviciding operations have been 
resumed, and experiments are under way to test the possibility of seeding canals 
with fish that feed on mosquito larvae. 
Nevertheless. a parasite transmitted by a mosquito has endangered one of the most 
promising and dynamic developments in Africa. Who can tell what the Gezira 
would be like today had not a tiny micro-organism, invisible to the naked eye, 
interfered wilh man's will to better his lot? 
Disease as a way of life 
But this is ooly a small part of the picture. Dr David Rowe of the WHO Special 
Programme for R esearch aod T raining in Tropical Diseases writes: 
"It is difficult for those living in temperate climates with good standards of public 
health and medical care to realize the impact of disease on rural communities in 
the tropics. For example, if you happen to be born and grow up in rural Africa 
you are liable to harbour four or more different disease-producing organisms 
simultaneously. And yet, as a parent, you must be fit enough to work, or your 
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family will starve. In your village every child at times suffers the paroxysms of 
malaria fever and you and your wife will mourn the death of one or two children 
from thjs disease. The snails in the village pond carry schistosomiasis, and you 
do not consider it unusual when your children pass blood in their urine." 
"You take for granted the disfigured faces and fingerless hands of the beggars in 
the village street suffering from leprosy. Jf you Live near a river where blackfties 
breed, one in ten of your friends and neighbours will be blind in the prime of life. 
You know that waves of killing diseases such as measles and meningitis and 
perhaps sleeping sickness are liable 10 strike your village. But, lacking effective 
remedies, you tend to philosophize in the face of sickness. You make the effort 
to walk the ten miles to the nearest dispensary when you or your child is ill, but 
there may be no remedies, and it may be too late ... " 
The enemies within 
Malaria is one of the most widespread diseases in the world, affecting some 
200 million people. In some regions, malaria transmission is so intense that present 
efforts at mosquito control and disease treatment are totally inadequate. 
fn Africa, about one-fourth of all adults suffer from malarial fever at one time 
or another, and 01berl> are infected though they have developed a relative immunity 
and rarely have a ttacks. After the age of 12 months, almost every child in tropical 
Africa has malaria; at least one million children die of the disease every year. 
Jn other countries, such as India and Sri Lanka, where malaria bad regressed 
before, it is now resurgent. 
Schistosomiasis (Bilharziasis) 
Schistosomiasis is an insidious and debilitating disease caused by smaU worms 
belonging to the group of parasites caUed trematodes or flukes. The adult 
schistosome worms live in the blood vessels of infected persons. The most wide-
spread species is Scltistosoma mansoni, which affects the bowel and is prevalent 
throughout Africa, the Middle East, and eastern parts of South America. Three 
other species also commonly infect man, two of which affect the intestine while 
one damages the bladder and, later, parts of the urinary system . 
The eggs of the parasite are passed out in the faeces or urine of infected people 
and develop into larvae in fresh water. Here, they infect freshwater snails, in 
which they multiply, and then release large numbers of free-swimming larvae 
(known as cercariae) which can penetrate through the skin of a person entering 
tne water. 
Once in man, the larvae 6nd their way into the small blood vessels of the large 
intestine or bladder, where they mature into adult worms of both sexes (the female 
lives in a fold along the body of the male). 
The females are egg-laying machines. For possibly five years eggs are laid con-
bnuously and this process may last as long as 20 years in a small proportion of 
patients. Eggs that are. not excreted lodge in either the bladder and adjacent 
organs of the genito-urinary system. when S. ltaematobium is the infecting parasite, 
or in the intestine and liver, when S. mansoni or S. japonicum is the invader. 
In the advanced stages of l!rinary schistosomiasis the constant passage of blood 
in the urine is characteristic and the small contracted bladder induces difficulty 
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8 and marked frequency in urination. In some tropical areas, schistosomiasis of 
the bladder is associated with cancer. 
During the later stages of the intestinal types ofschistosomiasis, lack of appetite, 
nausea and loss of weight are frequent together with intermittent bouts of diarrhoea 
and passage of blood in the stools. The liver and spleen enlarge, fluid collects 
within the abdomen producing a bloated belly while, in contrast, the remainder 
of the body shows emaciation. 
Individual cases can be cured, but the injection of anti-schistosomal drugs, some 
of which contain antimony, can cause serious side-effects. 
Schistosomiasis is often a disease of rural development, as artificial lakes and 
irrigation canals are sources of infection containing very large numbers of larvae. 
This problem has been encountered in Egypt and Sudan since the building of the 
High Dam at Aswan, and in Ghana as a result of the construction of the Akosom bo 
Dam on Lake Volta. Similar problems have afflicted northern Nigeria where the 
proportion of the population infected around the lake created by the Kainji Dam 
has doubled in three years. Incidence has also increased in the Gezira region 
of Sudan. Even in the semi-arid Arabian peninsula, irrigation projects have 
resulted in the spread of the disease to regions where it did not previously exist. 
Planorbis snails. intermediate hosts of the agent of imestinal schistosomiasis. 
Filariasis 
Filariasis is another widespread disease wbich in various forms affects about 
300 million people throughout the world. There are at least eight fiJarial parasites 
that infect man. Wuchereria bancrofti and Brug/a malayi, t ransmitted by mosquitos, 
infect some 250 million people. mainly in West, Central and East Africa, Egypt, 
the Malagasy Republic, the lndian subcontinent, South-East Asia, China, the 
Pacific islands and the Philippines. 
The adult worms live in the lymphatic vessels and lymph nodes, obstructing the 
Bow of lymph, causfog io6ammation and swelling (elephantiasis) of the arms, legs, 
and genitals. 
Another filarial parasite is Loa loa, which is transmitted by a type of horse fly. 
Jt is prevalent in Cameroon, the Congo, southern Nigeria, and Zaire. Adull 
worms move around the subcutaneous coooective tissues, producing the charac-
teristic Calabar swellings, and sometimes cross the white of the eye, causing great 
discomfort. 
River blindness 
The most dramatic form of filariasis is onchocerciasis or river blindness caused 
by the worm Onchocerca vo/vulus, which is transmitted by a small insect, barely 
3 mm long, with the ominous scientific name of Simuli11m damnosum- tbe black.fly. 
Like many insects in the tropics, the female blacldly feeds on blood, and its bite 
can transmit the larvae of Onchocerca vo/vulus to the person on whom it feeds. 
Once in the human host, the larvae develop into long, threadlike worms less than 
a millimetre across but up to half a metre long. These worms live up to 15 years 
and produce millions of embryos that invade the skin and eyes. 
The blackfly breeds only in fast-flowing water rich in oxygen and nutrient matter, 
and tbe worm develops inside tbe fly only at a temperature of J8° C or above. 
Tn other words, the disease can be transmitted in circumstances existing chiefly 
in tropical regions where it is hot and where there are fast-flowing rivers. 
Because of the heat, farmers in such areas work naked from the waist up and with 
legs bare. Thus they are exposed to the merciless attacks of black.flies. lo endemic 
regions, the black.flies a re so numerous that there is no way of keeping them off. 
A man may suffer several thousand blackfly bites a day, each of them a source 
of Irritation and a potential source of infection. 
At first the infection usually goes unnoticed. The larvae develop very slowly. 
A year or more later tbey become adult worms that settle in tissues under the 
skin and produce characteristic nodules. Each female worm produces thousands 
of embryos which invade the skin and may cause uncontrollable itching. Some-
times they also invade tbe eyes. The victim may then go slowly blind. 
Jn some regions of tropical Africa the sight of a young child leading a string of 
grown men through a village is a com mon one. The men look old, al though few 
of them are over 35 or 40. Some are like walking skeletons, their bones protruding 
under the skin, their eyes sightless. The child leading this macabre procession is, 
most likely, also infected. 
Many adolescents a lready show the effects of the disease: the skin is wrinkled 
and nodules containing adult worms can be seen under the surface. Some youngsters, 
already suffering from partial blindness, one of the early manifestations of oncbo-
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cerciasis, walk hesitantly round the village at dusk, their hands extended in front 
of them, feeling for obstacles they cannot see. 
In the upper basin of the Volta River the number of oncbocerciasis sufferers is 
estimated at over a miWon, and many thousands are blind. A special oncho-
cerciasis control programme has been launched in Benin, Ghana, the Ivory Coast, 
Mali, Niger, Togo and Upper Volta, seven of the most severely affected countries. 
The programme includes the insecticide spraying of inaccessible rivers fro m 
helicopters to control the blackfly and bait transmission of the disease. T he 
treatment of persons al ready infected is made difficult by the lack of non-toxic 
drugs that are effective against the adult worms. 
Other tropical diseases 
Malaria, scbjstosomiasis and filariasis are the three massive tropical infections. 
But there is a score of other tropical diseases, most of them caused by organisms 
that prey on man- his liver, blood, heart, brain, and gut. 
There are roundworms and ftatworms that invade the intestine ; hookworms that 
feed on the membrane of the small bowel; single-cell amoebae that anack the 
intestine and liver ; corkscrew-shaped trypaoosomes that burrow into the brain 
to cause sleeping sickness or, in South Amenca, Cbagas' disease (a form of 
trypanosomiasis that damages the heart); the slowly reproducing leprosy bacilli 
that mutilate and disfigure; intracellular parasites that cause leishmaniasis, with 
its two particularly severe forms : espundia in South America, which eats away 
the face, and visceral leisbmaniasis or kala azar, fatal within two years if not 
treated. 
Such is the added health burden carried by those peoples who live in tropical 
countries. 
Control of 011chocerciasis. or rive1· bf111d11ess. 
at presem depends on destroying th.: 11ector. 
Srmulium damnosum- t/1e blackjly The :.eq11e11ce 
shows, from left ro right and top to botTom: 
bluckjly larvae, enlarged to seven limes life size; 
a dam with fa.u-jfowi11g woter, where the blockfly 
larvae dei•elop, captured black/lies; n blackjly • 
. rli'ghrly over 2 millimetres long, sturrs feeding 
011 /11m1a11 blood; the same fly, bloated after 
feeding : adults blinded by 011chocerciasis ore led 
by children; a "hlind 11i1101:e", aba11do11ed wirh the 
exception of a few old blind persons. 




Trying out a new insecticide agftlnn 
malaria. /11 this photo, a member of the 
field research team is shown checking a 
mosquito breeding-place . 
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MOSOUITOS 
I here are very many different species of mosquitos, and ' all share certain common characteristics. They Jay their eggs in water, and the larvae that come out of these eggs live in the water, breathing air through a kind of 
tube, somewhat like the snorkel of a submarine. In a week or more Jarvae 
become pupae, a transitional, immature form, and then adult mosquitos. 
There are mosquitos all over the world, not only in warm tropical countries, 
where they are present all year round, but even in cold, northern regions such as 
Alaska, Greenland or northern Siberia. 
The feed ing habits of male mosquitos are much like those of the butterfly, lfrnjted 
to extracting nutrient substances from vegetation. But the females of certain 
species need human blood. These females have a proboscis, a tubular sucking 
organ capable of perforating the skin of man and aoimaJs. Their highly perfected 
bloodsucking system makes use of anaesthetic substances in the saliva, injected 
immediately at skin penetration, which may render the bite totally painless. 
The saliva thus introduced into the host can also contain disease-causing organ-
isms: parasites that cause malaria and fi lariasis. and viruses that can cause yellow 
fever, dengue, and encephalitis. 
Four species of mosquito-borne malaria parasites can infect man: Plasmodium 
fa/ciparum, P. vivax, P. malariae, and P. ovate. They provoke different forms of 
disease and react differently to antimalarial drugs. 
Inadequate w eapons 
There are ways of treating individual cases of malaria, and ways of preventing 
them. But oo single method has been developed that succeeds jo protecting all 
of the people at risk or tre.ating all those affected by the disease. 
One possible approach is to attack the mosquito itself, the "vector". DDT and 
other insecticides have permitted spectacular successes io some parts of the world. 
In India there were 75 mjllion cases of malaria in 1935, and a vigorous vector 
control campaign reduced the number to 60000 in 1962. 
But several factors come into play to prevent the total eradication of malaria in 
many areas, and even to reverse the trend in others. Mosquitos have developed 
resjstance to some insecticides and in the past few years the cost of insecticides 
has more than doubled. The cost of operating vehicles has also increased and, 
in addition, international assistance programmes have been reduced. 
As a result, many countries simply can no longer afford to carry out antimalarial 
campaigns as vigorously as they bave done in the past. Thus in India, for instance, 
the number of cases rose from a low of 60000 in 1962 to more than four million 
in 1974-a 70-fold increase. In Africa, the situation is even more serious since 
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14 there is no hope for large-scale antimalarial operations in the foreseeable future. 
Dr Adetokunbo 0. Lucas, former chairman of the Nigerian Medical Research 
Council, who has been appointed director of the WHO Special Programme for 
Research and Training in Tropical Diseases, points out that several intensive, 
well-supervised pilot and research projects in the African savanna have shown 
that infection is so deeply entrenched in the environment that spraying of insecticides 
and drug distribution are not sufficient to interrupt transmission. 
Antimalaria l drugs 
For centuries, malaria has been treated with the bark of quinquina (or cinchona), 
a tropical tree, from which quinine was isolated in 1820. Quinine is the oldest 
and one of the most efficient antimalarial drugs, attacking the parasite when it 
develops in the red blood cell. But it can become dangerous when used in high 
doses, and even in low doses for people who are sensitive to it. Vomiting, 
diarrhoea, headaches, troubles of vision and hearing, even deafness, are among 
the side-effects. 
Other antimalarials have since been developed, notably chloroquine. synthesized 
in Germany in 1934, and its derivatives. These 4-arninoquinolines are among the 
major antimalarials used today. There are, however, limitations concerning their 
utilization on a large scale in endemic regions. Some require prolonged administra-
tion when a person has been infected, others must be given regularly whenever one 
risks exposure to infected mosquitos. Shortage of health care facilities in most 
endemic areas makes this impossible, and in most of the affected countries a suffi-
cient increase of health personnel is not foreseeable in the near future. 
Furthermore, in vast regions of the world the parasites have become resistant to 
some of the major drugs. This is a very dangerous situation. For instance, 
Plasmodium falciparum resistance to 4-aminoquinolines occurs in some countries 
in South America, Asia, and the western Pacific. In Asia resistant strains have 
progressed westwards to reach the Indian subcontinent. If resistance crosses the 
Arabian peninsula, it could represent a great threat to the African continent, 
where Plasmodium falciparum is the main malaria parasite and chloroquine and 
other 4-aminoquinolines are the major antimalarial drugs. 
Clearly, the existing antimalarial drugs are insufficient for the operational demands 
of a control programme, and there has not been great fundamental progress since 
the synthesis of chloroquine more than 40 years ago. 
The promise of vaccines 
There is promise in recent research for a malaria vaccine, but progress is slow, 
although it is known that many infected people do develop an important degree 
of protective immunity. 
The picture is simi larly disappointing with regard to most other tropical diseases. 
There are no fully satisfactory drugs to control or eradicate them, and no vaccines 
to prevent them. 
Yet, modem biomedical science has progressed in giant steps. In the past 20 years 
or so it has unveiled some of the deepest secrets of life and made it possible to 
alleviate previously incurable diseases. 
But it bas not given tropical diseases the attention they deserve, even if they are 
judged only by the simple criterion of the number of people they affect. 
Shading indicates areas at risk for malaria. 
As publlsMd In lh< WHO Weekly Epidemioloaical Record, 
Vol.SI; No. 24 , Paats 190-191, 11 June 1976. 
Adult Anopheles stephensi, a mosquito that 
tra11smits the malaria parasite. 

A PLANNED COMMITMENT 
I cience today has a deep insight into the nature of life processes. Modern molecular biology bas permitted the understancting of the genetic code, which is far more complex and infinitely smaller in scale than any man-
made integrated electronic circuit. We can now decipher the code used to transmit 
the genetic message from generation to generation, and we know the path of 
transmission from the gene to the cell-factory that will produce whatever bas been 
ordered. We know that the basic mechanism is the same whether the end product 
is a bacterium, a parasite, or a man. 
In the 1970s, a gene was put together in the laboratory and the chemical and 
spatial structure of immunoglobulins, responsible for the organism's defence 
against foreign aggression, was analysed and described. Genetic engineering 
now makes it possible to break up genetic material and rearrange it in combina-
tions unlikely to have occurred in nature. The possibility thus exjsts that common 
gut bacteria may be " instructed" to produce antibocties against harmful viruses 
or to synthesize protein from atmospheric nitrogen. 
This extraordinary progress in molecular biology was accompanied by certain 
spectacular advances in mecticine-the result of conscious, planned commitment 
of skilled manpower towards selected goals. 
Vaccines to prevent, and drugs to treat, many of the diseases that have plagued 
humanity have been developed. Sophisticated treatments, using hormones and 
hormone-like substances, anti-viral chemicals and enzymes, have permitted the 
treatment of hitherto incurable diseases. Neuro-active drugs have made possible 
new approaches to the treatment of mental illness, and cancer research has made 
some forms of the disease curable. 
The neglected diseases 
But what of the tropical diseases that are. as they have always been, a major 
plague of humanity? 
Here the natural lag between discovery and application bas been prolonged and 
continuing. The broad base of knowledge available has not yet been exploited 
for a concerted attack against the tropical d iseases. They have benefited, of 
course. from some of the " fallout" of research. But in relation to the number 
of people they affect and their impact, they have been grossly neglected. The late 
Professor Jacques Monod, a Nobel-Priize-winner in molecular biology, called this 
neglect ''a disgrace". 
A mere pittance of money and effort goes towards tropical disease research. 
Total worldwide annual expenditures devoted to research on all tropical ctiseases 
is about US $30 million, the cost of building a few miles of motorway. 
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18 Biomedical research has not yet been applie-0 to tropical diseases in the methodical, 
purposeful fashion which has made it possible to answer some of the fundamental 
riddles of life and to develop the powerful tools of modern medicine . 
.. The comparatively modest progress in the development of new control techno-
logies for tropical diseases is in no sense an indictment of the professional re-
searchers in this field," points out Professor G.J. V. Nossa I, Director of the Walter 
and Eliza Hall Institute of Medical Research, Melbourne, Australia, and consultant 
to the WHO Special Programme, "rather, it is the result of disordered global 
priorities in health research which have limited the supply of such researchers ... 
The Special Programme is conceived as a giant step toward rectifying this im-
balance." 
We simply do not know enough about the biology of the parasites or bow they 
elude the defences of their human hosts. Our ignorance is a barrier to more 
intelligent implementation of control measures. A oew approach must be made. 
To study the enemy 
Parasites are small animals belonging to lowly groups: protozoa and worms of 
various kinds. lo most cases they are completely incapable of independent life 
and rely for survival on the highly specialized environment provided by two or 
three, or sometimes more, successive hosts. 
"When we come to think of it,·· says Professor Christian de Duve, another Nobel-
Prize-winner in medicine, "they really have major weaknesses and must be quite 
vulnerable. My strategic recommendation, therefore, is that the forces of the new 
biology be enlisted for a detailed analysis, at the cellular, subcellular and molecular 
level, of the various parasites that infest man, and of their relationships with their 
human and animal hosts. l have no doubt that out of such a study, powerful 
new preventive and curative means wiJI emerge." 
Professor de Duve, who bas unveiled the role of a specialized cell structure called 
the lysosome, has already carried out preliminary experiments that have confirmed 
the potential effectiveness of this approach. 
"Lysosomes," be says, "are essentially miniature little stomachs, wbich occur in 
all celJs. One of their principal functions is to serve in the digestion of food 
'eaten' by the cells by a special capture process. As with humans, cells may be 
greedy or frugal, aod they may exhibit a wide variety of tastes. Our purpose is 
to take advantage of these differences to kill certain cells selectively by poisoning 
their favourite food. To do this, we bind the poison to a carrier molecule in such 
a way that it will be released when it gets in the lysosome, that is, in the stomach 
of the cells that have eaten tbis poisoned food." 
Experiments in mice carried out by Professor de Duve and bis colleagues have 
indicated that such "selective poisoning" may be effective against Trypanosoma 
cruzi, the agent of Chagas' disease. This approach must also be tried against 
diseases such as schistosomiasis or onchocerciasis, caused by worms with verY 
tough skins, whose weak points may be their ''stomachs." Even the leprosy 
bacmus, which bas no lysosomes of its own, may be vulnerable to lysosome 
therapy because it lives and proliferates within the lysosomes of some of the 
patient's cells. 
Upper photo: Parasites in 
lysosomes, as seen by the 
electron microscope. The large 
element 011 the right contains 
011 apparently i11racr 
trypanosome, the parasite 
causing African trypanosomiasis. 
The element 011 the left 
contains 011 almost completely 
digested trypa11osome. Bar in 
lower right-hand corner 
represe111s one-millionth of a 
millimetre. 
An electron microscope photo 
of a macrophage, one of the 
scavenger cells of the body 
normally responsible for killing 
infectious agents. However. 
some parasites such as 
Leishmaoiafind a way to rake 
refuge, grow, and breed in 
macrophages. 
20 A major breakthrough 
In April 1976, Professor William Trager of the Rockefeller University in New 
York, a member of the Special Programme's Scientific Working Group on 
Immunity to Malaria, announced that he had succeeded in maintaining for lhree 
months a laboratory culture of Plasmodium falciparum. The parasite had gone 
through many multiplication cycles in human blood celJs. 
This is the first time that a continuous in vitro culture of a human malaria parasite 
has been successfully established. It is a major breakthrough because large 
amounts of P. falciparum will now be available for research purposes, and there 
is renewed hope in the possibility of developing a malaria vaccine. 
Immunization has permitted the control of many viral and bacterial infections. 
But there are no effective vaccines against the tropical diseases. There are, 
however, strong indications that vaccines could be developed against many of 
them if only the required concerted effon were undertaken. 
Any disease agent is foreign to its host organism, and we should find out how it 
protects itself against rejection. Different protection mechanisms have already 
been identified in different organisms. 
Recent research has shown, for instance, that the S chistosoma parasite has a very 
elaborate system to ensure its survival in spite of the immunological defences of 
the organism it invades. 
When a free-swimming larva penetrates through the skin it is "recognized" as a 
foreign organism, and antibodies are produced against it. The attack, however, 
is still weak, and while it gathers strength the parasite has a few days to reach 
maturity. When it does, it covers its own antigens (the surface proteins that 
identify it as an enemy) with proteins that appear to be copies of the antigens of 
the host itself. It becomes a " wolf disguised in sheep's clothing". 
One line of attack could be to immunize to increase the reaction against the larva, 
so destroying the adult parasite before it had time to protect itself. 
Immunization against leprosy is likewise a feasible goal, and it is already actively 
pursued by a scientific working group of the Special Programme. 
This microscope sequence shows the invasion of a red blood cell by a malaria 
parasite (arrow). The parasite becomes attachetl ro rhe red blood cell ( left) and there 
is a marked dis1orrio11 of rhe cell (centre) followed by a relatil•ely slow invasion 
of tlte red blood cell by rhe parasite. 
J 
Towards high technology 
But the development of vaccines, which could permit the control of parasitic 
diseases (and perhaps the eradication of some of them), may require the input of 
many disciplines, such as molecular biology, genetics and cellular immunology, 
in addition to parasitology. It may require, for instance, the avaiJability of large 
sources of parasites free from contamination. This, in turn, may require the 
culture of insect tissues in which to grow parasites. (The development of the 
poliomyelitis vaccine was made possible because scientists learned to grow 
mammalian cells outside the body by the technique known as tissue culture.) 
Insect tissue culture may, in turn, require the use of sophisticated biophysical 
fractionation methods to separate different classes of cells from one another. 
Also, we need to know more about the biology of the parasite and the mechanisms 
by which it eludes the defences of the human host. This knowledge may require 
deep insight into the molecular organization and peculiarities of the parasites. 
In other words, frontier disciplines of biomedical sciences must be associated with 
parasitology in a concerted effort at developing vaccines. And this applies also 
to other possible approaches. 
A lymphocyte cell (right), 
one of the white blood 
cells which are a major 
element of the organism 's 
immunological defence system. 
Preparation of measles 
vaccine at the Tirana , 
Albania, Institute of 
Hygiene and Epidemiology. 
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22 Drugs designed to interfere with enzymes are one of these. Enzymes are large 
molecules required in minute amounts by living organisms to carry out the most 
complex chemical reactions. Their action is very specific, but it bas been shown 
that competitive molecules can be used to "fool" the organism and thus interrupt 
certain vital processes. For example, fertilized eggs of nematode worms, some of 
which are parasites of man, manufacture chitin, a substance which renders the cell 
tough and impermeable ; since mammals do not produce chitin, interference with 
the enzymes needed to produce chitin could destroy the eggs without affecting the 
human host. 
Both enzymology and genetics, as well asotherscientilicdisciplines, can be involved 
io new approaches. For example, an important finding made io 1975 shows that 
some people possess a genetic factor that prevents the invasion of red blood cells 
by certain malaria parasites. This genetic trait conferring malaria resistance is 
called "Duffy negative" because red cells lack the Duffy antigen, named after the 
first person in wbom it was discovered. 
These Duffy antigens tell us which are the susceptible red blood cells. There 
is a ''keyhole" on the blood cell, to which the parasi te possesses the "key". If the 
keyhole does not exist (in Duffy-negative people) the blood cells are protected 
against the parasites. Laboratory experiments indicate that the "keyhole" can 
also be blocked by certain enzymes that remove the Duffy antigen. 
Vector control 
Vector control. likewise, can benefit immensely from research, especially in the 
a rea of biological vectors. 
Experiments have shown. for instance, that tiny worms can kill the tsetse fly, the 
vector of the sleeping sickness parasite. Basic research into the biology of the 
insect and of its predator and exhaustive study of the potential ecological dangers 
of such an approach are obvious prerequisites. 
These approaches are " high technology" approaches, such as have made possible 
the development of the poliomyelitis vaccine or of the vast raoge of antibiotics 
against bacterial infections. High technology remedies are the result of the applica-
tion of fundamental knowledge. They are often spectacularly successful and, once 
available, they are usually cheap to produce and apply. But their development 
requires the commitment of skilled manpower and adequate budgets. One of the 
purposes of the Special Programme for Research and Training in T ropical Diseases 
is to evaluate possible approaches, plan specific lines of research, select the scientists 
most qualified to carry it out, and give them the means to work. 
Rhodnius prolixus, a vec-
tor of Chagas' disease. 
Phlebotomus papatasi, a 
vector of /eishmaniasis. 
A LEPROSY VACCINE? 
I 
ow is goal-oriented research to be carried out under the Programme? 
An example is provided by the fMMLEP scientific working group, which 
met for the first time in November 1974. A scientific working group is a 
group of scientists working towards a defined goal, and IMMLEP stands for 
immunology of leprosy. The goaJ is to develop immunological knowledge of this 
disease with a view to perfecting diagnostic methods and eventually producing 
an effective vaccine. 
Leprosy is one of Ole most perplexing infectious diseases. The leprosy bacillus 
was first described by Dr Armauer Hansen, a Norwegian, more than a century 
ago, but no claim of success with in vitro growth has yet been confirmed. 
Hansen's bacillus (or Mycobacterium leprae), which in so me respects resembles the 
bacterium that causes tuberculosis, is protected by a waxy layer and is characterized 
by its slow multiplication, which accounts for the long incubation period of 
leprosy- often several years. 
Atleast 10 million people in the world are suffering from leprosy. The mode of 
transmission of the disease is not well understood. It is generally admitted that 
transmission is from man to man. 
Some 15 years ago researchers succeeded in growing the bacillus by inoculating it 
into a mouse's footpad, but only small amounts of bacilli can be harvested with 
this technique. This shortage of bacilli was a major obstacle to further progress, 
including the possible development of a vaccine. 
Armadillos make news 
Then, a major breakthrough occurred. ln 1971, researchers in Louisiana in the 
USA discovered that injection of M. leprae into nine-banded armadillos caused 
massive infection in some of the animals. For the first time, the harvesting of 
large numbers of bacilli for research became possible. 
One of the important steps in developing a vaccine involves the methods for 
measuring, first in laboratory animals, then in man, the protective effect of candidate 
vaccine preparations. 
These methods make use of antigens, the particular components of the parasite 
which, when incroduced into an organism, trigger a specific immune response. 
The antigen preparation and purification is a complex task. One of the major 
objectives of the 1MMLEP group has been to prepare antigens suitable for field 
use in skin testing. 
By the time the IMMLEP group met again at the beginning of December 1975 
considerable progress had been made on this first objective, the development of 
a leprosy-specific skin test, and three promising antigenic preparations had been 
23 
24 developed from infected armadillo tissue: one prepared in Venezuela, one in 
the United Kingdom, and one in the USA. 
Some preliminary tests on human volunteers b.ad been carried out. The results 
were promising, and the lMMLEP scientific working group decided to use the 
tests in areas where leprosy is not endemic (to avoid distortion of results by the 
possibility of previous infection) and where the influence of BCG vaccination, 
and of possible exposure to other common mycobacteria can be taken into 
consideration to the greatest extent possible. 
Tests in England and Norway were due to start early in 1976, and a tight schedule 
of operations had to be set up. Some infected armadillos were available at the 
National Dermatology Institute in Caracas, and additional material was to be 
shipped there no later than 15 December 1975. Fractionation of antigens started 
immediately, and by early January 1976 the antigenic preparation was sent by air 
(on ice) from Caracas to London for coding and distribution to the various centres 
involved. 
Methods based on the most up-to-date biomedical techniques were then used to 
analyse with precision the results of the IMMLEP trials. They include skin tests 
for delayed hypersensitivity, in vitro tests to determine immune response, and tests 
to measure the level of circulating antibodies combined with mycobacterial antigens. 
These investigations must be performed by highly experienced personnel and often 
require sophisticated and costly equipment. 
Thus another step was taken with development of a skin test, the diagnostic aid 
in the search for a vaccine against leprosy. There is no absolute certainty at this 
time what type of vaccine can be made or what type is needed for the control of 
leprosy, though the prospects for developing an effective one are hopeful. 
The 11i11e-ba11ded armadillo, 
first source of large amounts 
of tlte leprosy bacl/lus. 
Above: Before a nurse administers 
the injection of dapsone for treatmem 
of children with leprosy, the children 
are weighed and the amount of 
dapsone to be given is calculated by 
weight and marked on their backs. 
Above right: A mother, mutilated 
by leprosy, holds her child, already a 
victim of the same disease. They live 
in a lone/)' spot in the bush with a 
group of others who share their plight. 
Electron microscope view of the 
leprosy bacillus obtained from arma-
dillo. 
26 To break the deadlock 
In one of its reports, the IMMLEP group indicated that, "Given a source of 
antigen, it is virtually certain that one or more of these agents can be adapted 
for use in a practical vaccine that would provide long-term protection against 
M. leprae and might even be used to break the immunological deadlock that 
develops in lepromatous leprosy." 
Now, a tentative schedule has been established: if all goes well, field trials of a 
vaccine could start in 4 or 5 years, and would be followed by varying periods of 
observation which are required due to the long incubation periods of leprosy. 
As the IMMLEP programme progresses with the improvement of diagnostic 
techniques (2 to 4 years), the possible development of a vaccine (10 to 20 years), 
and immunotherapy (4 to 6 years) it will be backed up and strengthened by better 
and more effective chemotherapy. For this purpose, a Chemotherapy of Leprosy 
(THELEP) programme is being formed. 
These intensive research efforts can be expected to take us past a significant 
milestone in the century-old fight against leprosy. 
This child, who lives in a Leprosarium, shows early signs of leprosy. 
AN ACTIVE PARTNERSHIP 
I iven adequate resources and a careful selection of priorities. new knowledge in biomedical sciences can radically alter the course of the uphill fight against tropical diseases, most of which are out of control. 
Vaccines against leprosy and malaria can reasonably be expected in the next 10 
to 20 years. Better knowledge of parasites will inevitably improve the prospect 
for vaccines against schistosomiasis, trypaoosomiasis, and leishmaoiasis. 
Reliable and practical diagnostic techniques and better drugs, with Jess serious 
side-effects, will result from concerted research into parasite function and biology. 
Until now, most of the anti-parasitic drugs have been selected empirically through 
large-scale screening, rather than developed specificaUy to penetrate into the chinks 
in the parasites' armour. 
The investment required is minimal compared with the results that can be expected. 
In endemic areas productivity is frequently decreased, and during epidemics the 
entire work force of an area may be disabled, preventing the planting or harvesting 
of crops. The prevalence of diseases may dictate the distribution of a population. 
For example, human occupancy of large areas of Africa, Asia and tbe Amazon 
region of South America have been impossible due to malaria, trypanosomiasis, 
or onchocerciasis. 
The impact of parasitic diseases on cattle and domestic animals should not be 
omitted from this balance sheet. In Africa alone, about 10 million square kilo-
metres of land are infested with tsetse llies. If cleared of the vector, this land 
could provide for a potential cattle population of J 25 million. Thus the Special 
Programme will work in cooperation with the [nternational Laboratory for Re-
search in Animal Diseases set up in Nairobi, Kenya, sharing with it fundamental 
knowledge needed to develop new tools for the control of trypanosomiasis. 
The task to be accomplished is not an easy one. It is a major effort, and it 
represents more than a scientific endeavour. It is a form of operational research, 
requiring managerial skills, financial expertise, political experience, and organiza-
tional capabilities in addition to the speciaUzed competence of scientific researchers. 
Preliminary meetings concerning tbe Special Programme and scientific meetings 
devoted to specific diseases have already been held in Geneva and elsewhere. 
The Special Programme is co-sponsored by the World Health Organization and the 
United Nations Development Programme. During the first meeting in 1975, several 
countries and agencies contri buted sufficient funds to carry on preparation and 
p lanning of the Programme for the first year in an attempt to determine the most 
efficient way to carry it out, to select participants, to determine goals, and to work 
out schedules and budgets. 
27 
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A researcher in Iran examines snails for the presence of parasites causing schistosomiasis. 
The plan 
Discussions among experts in various fields of biomedical research, specialists in 
tropical diseases, health authorities of several countries, and WHO staff, indicated 
that a two-pronged approach was necessary: 
• To enlist the specialized knowledge and technological facilities in different areas 
of biomedicine that are available chiefly in the industrialized countries. 
• To associate this with research and clinical work already being carried out in 
the very countries most affected by major tropical diseases, by strengthening 
existing institutions, and training additional scientific personnel. 
At the beginning, the Programme will focus on the institutions in one continent, 
the one that carries the major burden: Africa. The concept of the plan is global, 
however, and research centres on other continents will participate in it. It will 
concentrate on six diseases: malaria, schistosomiasis, filariasis, trypanosomiasis, 
leprosy and leishmaniasis, which constitute the crux of the problem. 
The plan is to enlist and support existing laboratories and clinical research centres 
in several tropical countries and to develop new laboratories where necessary. 
It is hoped that many or all of the 25 or so medical schools in tropical Africa will 
become key participants in this work since the medical personnel being trained 
there will inherit the responsibility of providing health care in the region and of 
carrying out research on local disease problems. Already, the Government of 
Zambia bas made a generous offer of facilities for a multidisciplinary tropical 
diseases research centre. 
At the same time, research centres in industrialized countries and the pharma-
ceutical industry will share their knowledge in an active partnership with the 
Programme. Their aim will be to develop new remedies and promote scientific 
self-reliance so that people in different lands, facing different sets of conditions, 
can solve their own problems with the best available means. 
A child in Thailand is exami11ed for enlarged spleen, a sign of malaria. 
Below: A health worker analyses samples of excrement and urine collected i11 a village. 
30 
THE TIME IS NOW 
I s distances between all parts of the world are effectively shortened by modem systems of communication and transport, countries and people everywhere are growing increasingly interdependent. The words of John 
Donne written almost 400 years ago, "No man is an island, entire of itself", 
remain as a timely warning to us today. Without leaving our homes we are 
witness to events occurring in distant places, and we follow their progress with 
interest or concern. Even if we sometimes choose not to see or to hear, and for 
a time tum aside to attend to our own lives, we cannot escape involvement, and 
it is dear that a new global consciousne"8s is emerging that was unprecedented in 
any earlier age. 
One of the major cha!Jenges of our time is health. Good health is now widely 
recognized as a fundamental human right for all people, and acceptance of this 
proposition implies that human society must shoulder the burden and accord the 
highest priority to ways and means of achieving that goal. 
How is this to be done? 
Science certainly bas a paramount role to play. It has contributed to providing 
many with the means to lead a good life, but many more have been left out of 
the mainstream, struggling not only for a decent life, but for survival. 
Goal-oriented science 
If the goal of reaching an acceptable level of health for all within the next 20 or 
30 years is to be achieved, the keystone will be political action. Sufficient priority 
must be given to health in relation to other goals such as industrialization and 
economic growth. An essential correlation is often ignored: in general, healthier 
people make more productive workers and wealthier citizens. 
Health cannot be isolated from its social context. Poverty, malnutrition, poor 
hygiene, lack of education, inadequate housing, unemployment or poor working 
conditions, and pollution, as well as the presence of viruses, bacteria, parasites, 
and other disease-causing organisms, are factors predisposing to ill health. The 
cumulative action of these factors leads at the present to unacceptable disparities. 
In some developing countries, as many as half of the children die before reaching 
their fifth birthday; childhood mortality rates in these countries are about 50 times 
higher than those in the developed world. 
The conquest of major parasitic diseases may not mean health for all, nor can 
the purposeful harnessing of science guarantee their conquest. But it is certain 
that health for all cannot be achieved wjthout this conquest and that this requires 
better tools, which science can provide. It would seem that the investment is 
minimal in comparison with the return that can reasonably be expected. The 
initiaJ yearly cost of the Special Programme for Research and Training in Tropical 




ARCHU Tropical diseases. 
DOROZY no.22 
c.1 22099 
11111~ 911 111111111 llH ~I~ I~ II~ 
107396 
Text by A. Dorozynski, Associate Director, Publications, International Develop-
ment Research Centre (IDRC), Toronto, Canada, in cooperation with World 
Health Organization (WHO) staff. 
Design and layout by S. Clerget-Vaucouleurs. 
Photos and drawings: 
Cover, WHO, by Monique Jacot ; pp. 2, 8, 12, 15 (map & photo), 16, 22 (right), 
and 29 (top and bottom), WHO; pp. 5, 21 (bottom), and 31, WHO, by D. Heo-
rioud; p. 6 (top), WHO, by E. Schwab; p. 6 (centre), WHO, by P. Larsen; p. 6 
(bottom), 25 (upper left), 26, WHO, by Pierre Pittet; p. 10, WHO, by E. Mandel-
mann; p. 24 (drawing), by S. Clerget-Vaucouleurs; p. 19 (micrograph above), 
International Institute of Cellular and Molecular Biology, Brussels, and photo 
(below) by Dr. J. Mauel and Dr. T. Jalenti ; p. 20, US National Institutes of 
Health ; p. 21 (top), Rockefeller University, New York; p. 25 (upper right), 
WHO, by Ernst Scheidegger; pp. 22 (left), 28, WHO, by Paul Almasy; p. 25 
(micrograph at lower right), National Institute for Medical Research, Medical 
Research Council, London. 
Produced by WHO, witlz the support of the IDRC. 
Printed in Switzerland 

